145 related articles for article (PubMed ID: 36607375)
1. Exceptional Response of Rare Plasmacytoid Variant Prostate Cancer Post 177Lu-PSMA Therapy Seen on 68Ga-PSMA PET/CT.
Maharaj M; Heslop L; Govender T; Korowlay N
Clin Nucl Med; 2023 Feb; 48(2):e69-e70. PubMed ID: 36607375
[TBL] [Abstract][Full Text] [Related]
2. 68Ga-PSMA PET/CT Images of Multiple Cutaneous Metastases in a Patient With Prostate Carcinoma: Complete Response to 177Lu-PSMA-617 Treatment.
Sivrikoz IA; Deveci H; Ak AM; Acer E
Clin Nucl Med; 2023 Nov; 48(11):950-952. PubMed ID: 37812519
[TBL] [Abstract][Full Text] [Related]
3. The meta-analysis of the effect of 68Ga-PSMA-PET/CT diagnosis of prostatic cancer compared with bone scan.
Zhao R; Li Y; Nie L; Qin K; Zhang H; Shi H
Medicine (Baltimore); 2021 Apr; 100(15):e25417. PubMed ID: 33847640
[TBL] [Abstract][Full Text] [Related]
4. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
5. Unusual Case of Diffuse Penile Metastasis of Prostate Cancer on 68Ga PSMA PET/CT Imaging and 177Lu PSMA Posttherapy Scintigraphy.
Vadi SK; Kumar R; Mittal BR; Parihar AS; Singh SK
Clin Nucl Med; 2018 Apr; 43(4):276-278. PubMed ID: 29465493
[TBL] [Abstract][Full Text] [Related]
6. 68Ga-PSMA Uptake in Brain Metastasis of Gastric Carcinoma.
Kesim S; Oksuzoglu K
Clin Nucl Med; 2022 Sep; 47(9):e585-e586. PubMed ID: 35930713
[TBL] [Abstract][Full Text] [Related]
7. Delayed 68Ga-PSMA PET/CT Image-Guided Biopsy for Low-Grade Adenocarcinoma in Benign Prostatic Hyperplasia.
Santhosh S; Jeeva G
Clin Nucl Med; 2021 Apr; 46(4):e190-e192. PubMed ID: 33234940
[TBL] [Abstract][Full Text] [Related]
8. PET/CT With
Giovacchini G; Giovannini E; Riondato M; Ciarmiello A
Curr Radiopharm; 2018; 11(1):4-13. PubMed ID: 29090673
[TBL] [Abstract][Full Text] [Related]
9. Performance of 68Ga-labeled prostate-specific membrane antigen ligand positron emission tomography/computed tomography in the diagnosis of primary prostate cancer: a systematic review and meta-analysis.
Hu X; Wu Y; Yang P; Wang J; Wang P; Cai J
Int Braz J Urol; 2022; 48(6):891-902. PubMed ID: 34003611
[TBL] [Abstract][Full Text] [Related]
10. 68Ga-PSMA-11 PET/CT for prostate cancer staging and risk stratification in Chinese patients.
Zang S; Shao G; Cui C; Li TN; Huang Y; Yao X; Fan Q; Chen Z; Du J; Jia R; Sun H; Hua Z; Tang J; Wang F
Oncotarget; 2017 Feb; 8(7):12247-12258. PubMed ID: 28103574
[TBL] [Abstract][Full Text] [Related]
11. Atypical Presentation of Liver Metastases of Prostate Cancer in 68Ga-PSMA-11 PET/CT.
Stanzel S; Weitzer F; Janek E; Plhak E; Aigner RM
Clin Nucl Med; 2023 Dec; 48(12):1064-1065. PubMed ID: 37934704
[TBL] [Abstract][Full Text] [Related]
12.
Pfister D; Haidl F; Nestler T; Verburg F; Schmidt M; Wittersheim M; Steib F; Heidenreich A
BJU Int; 2020 Dec; 126(6):679-683. PubMed ID: 32531840
[TBL] [Abstract][Full Text] [Related]
13. Physiological 68Ga-PSMA-11 Uptake in Dural Venous Sinuses.
Kulkarni M; Joshi PV; Kumar K
Clin Nucl Med; 2024 Feb; 49(2):e58-e60. PubMed ID: 38178373
[TBL] [Abstract][Full Text] [Related]
14. Prostate-specific membrane antigen positron emission tomography in the management of recurrent prostate cancer.
Afaq A; Bomanji J
Br Med Bull; 2018 Dec; 128(1):37-48. PubMed ID: 30272121
[TBL] [Abstract][Full Text] [Related]
15. Thyroid Incidentaloma on 68Ga-PSMA-11 PET/CT Leading to Detection of Thyroid Metastasis in Metastatic Prostate Carcinoma.
Parghane RV; Basu S
Clin Nucl Med; 2022 Mar; 47(3):e300-e301. PubMed ID: 34690291
[TBL] [Abstract][Full Text] [Related]
16. Rare Case of Small Cell Metastatic Prostatic Adenocarcinoma, Properly Staged by 68Ga-PSMA PET/CT Scan.
Golestani ZB; Soltani S; Kalantari MR; Ghorbani HR; Aghaee A
Clin Nucl Med; 2022 Mar; 47(3):e259-e261. PubMed ID: 35025791
[TBL] [Abstract][Full Text] [Related]
17. Distinguishing Meningioma From Metastasis of Prostate Cancer on 68Ga-PSMA PET/CT.
Filizoglu N; Oksuzoglu K; Ozguven S
Clin Nucl Med; 2021 Nov; 46(11):e553-e555. PubMed ID: 34606488
[TBL] [Abstract][Full Text] [Related]
18. Potential Impact of
Calais J; Kishan AU; Cao M; Fendler WP; Eiber M; Herrmann K; Ceci F; Reiter RE; Rettig MB; Hegde JV; Shaverdian N; King CR; Steinberg ML; Czernin J; Nickols NG
J Nucl Med; 2018 Nov; 59(11):1714-1721. PubMed ID: 29653978
[TBL] [Abstract][Full Text] [Related]
19. Primary lymph-node staging with
Corona-Montes VE; González-Cuenca E; Fernández-Noyola G; Olarte-Casas MA; Bobadilla-Salazar D; Medrano-Urtecho HM; Asimakopoulos AD
Urol Oncol; 2021 Aug; 39(8):494.e1-494.e6. PubMed ID: 33223371
[TBL] [Abstract][Full Text] [Related]
20. A Multicenter Prospective Clinical Trial of
McCarthy M; Francis R; Tang C; Watts J; Campbell A
Int J Radiat Oncol Biol Phys; 2019 Jul; 104(4):801-808. PubMed ID: 30890448
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
